2023 Fiscal Year Research-status Report
Elucidation of bioavailability and anticancer property of momilactones and natural anticancer compounds isolated from rice
| Project/Area Number |
21K14818
|
|---|
| Research Institution | Hiroshima University |
|---|
Principal Investigator |
NGUYEN VANQUAN 広島大学, 先進理工系科学研究科(国), 研究員 (90883033)
|
|---|
| Project Period (FY) |
2021-04-01 – 2025-03-31
|
| Keywords | momilactones / anti-blood cancer / exogenous application |
|---|
| Outline of Annual Research Achievements |
- The anti-blood cancer capacity of momilactones A (MA) and B (MB) was confirmed and validated by MTT assay on other cancer cell lines including OUN-1, U937, THP-1, Jurkat, Molt-4, and YT. The IC50 values ranged from 0.5 - 5.0 ug/mL (safe for normal human cells). MB exhibited stronger activity than MA. Additionally, the cytotoxicity of MA and MB on pancreatic and lung cancer cell lines has been evaluated. The results are being analyzed and prepared for a manuscript.
- The preliminary study on exogenous application for improvement of MA and MB contents in rice and rice products was conducted. Accordingly, Koshihikari brown rice germinated under 75 mM salinity (NaCl) for 4 days impoved MA and MB contents by 3 and 2 times, respectively compared to control (0 mM, 4 days-germination). Besides, other isolated compounds tricin and p-coumaric also increased the contents 3 and 1.5 times, respectively at the same treatment. The results were published on Foods: https://doi.org/10.3390/foods12132501.
- Remarkably, we have successfully simplified the extraction process to obtain extracts rich in MA and MB from rice bran by applying the principle of freezing and thawing of raw materials combined with liquid-solid extraction using only one type of organic solvent. The results are being synthesized to prepare a manuscript.
|
| Current Status of Research Progress |
Current Status of Research Progress
3: Progress in research has been slightly delayed.
Reason
- We have perfected the extraction and isolation process of potential anticancer compounds from rice husk, including MA, MB, p-coumaric acid, and tricin. Additionally, we have simplified the extraction process to obtain higher concentrations of MA and MB compared to traditional methods.
- The anti-blood cancer activity of MA and MB has been validated through both cytotoxicity experiments and mechanism of action studies. Preliminary evaluations of their activities against pancreatic and lung cancers are underway.
- The experiments on momilactone combinations with synthetic drugs and other isolated compounds have not been completed due to the lengthy process of synthesis and analysis of end products. These experiments are currently in the process of optimizing procedures and will be carried out in the next phase of the project. Alongside comprehensive collaboration with Aichi Medical University, Kanazawa University, and Toyama University, we anticipate achieving significant results in the final stage of the project.
|
| Strategy for Future Research Activity |
- Study on absorbability of MA and MB through digestive tract of mice (in vivo digestion).
- To complete evaluating the anticancer activity of combinations of momilactones, tricin, p-coumaric acid, and other synthetic anticancer drugs.
- To evaluate anticancer ability of momilactone’s derivatives created by various hydrolysis and derivatization methods.
|
| Causes of Carryover |
In the next stage, we will focus more deeply on researching the feasibility of drug production from MA and MB, including the absorption capacity of MA and MB in in vivo models (mice) and enhancing the solubility and activity of MA and MB through specific formulations. Additionally, absorption mechanisms, specificity, and toxicity will be thoroughly investigated. Furthermore, synthesizing derivatives from MA and MB will aid in exploring new activities and producing new drug candidates from momilactones. The incurring amount will be mainly used for purchasing laboratory mice and chemicals for the synthesis of momilactone's derivatives.
|
